(a) Schematic illustration of the experimental protocol for Fig. 3. (b) qRT-PCR analysis of Bach2 and Prdm1 mRNA among activated Bach2+/+ ERT2cre B1-8hi or Bach2f/f ERT2cre B1-8hi B cells in spleen of NP-CGG immunized CD45.2+ wild-type recipient mice transferred with Bach2+/+ ERT2cre B1-8hi or Bach2f/f ERT2cre B1-8hi naive B cells with tamoxifen for 4 days before immunization. Samples were sorted at day 2 after immunization. (c) qRT-PCR analysis of Bach2 and Prdm1 mRNA in Bach2+/+Prdm1+/+ ERT2cre B1-8hi,Bach2+/+Prdm1f/f ERT2cre B1-8hi or Bach2f/fPrdm1f/f ERT2cre B1-8hi NP-specific donor GC B cells (NP+B220+CD38−GL7+) to check the deletion efficiency for Fig. 3c and 3e. (d) Intracellular flow cytometry of Bcl-6 expression in NP-specific donor GC B cells (NP+B220+CD38−GL7+) from experiments in Fig. 3e. The gray histogram represents the naïve B cells. **p < 0.01 and ***p < 0.001 (unpaired Student’s t-test). Data are representative of two independent experiments (b, c; mean and s.d. n=3 mice) and three independent experiments (d).